VEA
VKTX icon

Virtus ETF Advisers’s Viking Therapeutics VKTX Stock Holding History

Virtus ETF Advisers’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,485
Closed -$59.8K – 791
2024
Q4 		$59.8K Sell
1,485
-286
-16% -$16.3K 0.02% 451
2024
Q3 		$112K Buy
1,771
+33
+2% +$1.94K 0.05% 360
2024
Q2 		$92.1K Sell
1,738
-2,773
-61% -$182K 0.05% 350
2024
Q1 		$370K Sell
4,511
-306
-6% -$13.6K 0.2% 206
2023
Q4 		$89.6K Buy
4,817
+399
+9% +$5.22K 0.06% 405
2023
Q3 		$48.9K Sell
4,418
-439
-9% -$6.28K 0.03% 416
2023
Q2 		$78.7K Buy
+4,857
New +$102K 0.05% 430
2022
Q2 		– Sell
-32,708
Closed -$98K – 476
2022
Q1 		$98K Sell
32,708
-1,945
-6% -$6.98K 0.04% 307
2021
Q4 		$159K Sell
34,653
-318
-0.9% -$1.78K 0.06% 328
2021
Q3 		$220K Sell
34,971
-1,820
-5% -$11.2K 0.1% 244
2021
Q2 		$220K Sell
36,791
-7,964
-18% -$47.3K 0.09% 276
2021
Q1 		$283K Buy
44,755
+789
+2% +$5.55K 0.12% 251
2020
Q4 		$248K Buy
43,966
+1,459
+3% +$8.84K 0.1% 315
2020
Q3 		$247K Sell
42,507
-5,813
-12% -$40K 0.13% 267
2020
Q2 		$348K Buy
48,320
+3,100
+7% +$20.6K 0.16% 266
2020
Q1 		$212K Sell
45,220
-6,603
-13% -$40.6K 0.09% 273
2019
Q4 		$416K Buy
51,823
+19,672
+61% +$143K 0.07% 243
2019
Q3 		$221K Sell
32,151
-1,790
-5% -$13.3K 0.04% 231
2019
Q2 		$282K Buy
33,941
+5,087
+18% +$43.5K 0.06% 244
2019
Q1 		$287K Sell
28,854
-3,457
-11% -$28.9K 0.61% 62
2018
Q4 		$247K Sell
32,311
-7,649
-19% -$91.5K 0.04% 161
2018
Q3 		$696K Sell
39,960
-29,345
-42% -$349K 0.07% 77
2018
Q2 		$658K Buy
+69,305
New +$461K 0.58% 119

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Virtus ETF Advisers's VKTX Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 1,485 shares — an estimated $59.8K sold.

Virtus ETF Advisers first reported a position in VKTX in Q2 2018 and held it in 23 quarters. The position peaked at $696K in Q3 2018. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,485 Viking Therapeutics shares in Q1 2025, an estimated $59.8K.
  • Virtus ETF Advisers first reported a position in Viking Therapeutics in Q2 2018 and held it in 23 quarters.
  • Virtus ETF Advisers's Viking Therapeutics position peaked at $696K in Q3 2018.
  • 372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.